Prescription Drug Spending: What’s Coming Next for Medicaid and How Can States Prepare?
Experts at the NAMD Fall Conference discussed challenges with high-cost drugs.
Letter ·
NAMD Submits Comments on Medicaid Drug Rebate Program Proposed Rule
On July 25, NAMD submitted comments on CMS’s proposed rule on the Medicaid Drug Rebate Program (MDRP).
Author
- NAMD Staff
Focus Areas
On July 25, NAMD submitted comments on CMS’s proposed rule on the Medicaid Drug Rebate Program (MDRP). This proposed rule would create a drug price verification survey, under which manufacturers would be required to provide detailed data to CMS on certain high-cost drugs, along with definitional and operational changes to the MDRP.
NAMD appreciates CMS’s focus on high-cost drugs and strongly supports many of the provisions in this rule, including the proposed drug price verification survey, dispute time limits, and pharmacy benefit manager spread pricing policies. Medicaid Directors do, however, report concerns in response to CMS’s request for information on the impact of requiring a patient’s diagnosis be on a prescription as a condition of receiving federal match.
Related resources
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
On February 9, 2022, NAMD submitted comments on Medicare’s proposed National Coverage Determination (NCD) of Coverage with Evidence...
NAMD Urges CMS to Mitigate State Costs on Controversial Alzheimer’s Drug
In formal comments, NAMD calls on Medicare to step up and cover the Alzheimer’s drug Aduhelm. Failure to...
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.